SARC032-SU2C

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity

TYPE OF SARCOMA: Soft Tissue Sarcoma of the Extremity
DRUG: Pembrolizumab

ACCRUAL STATUS: Not recruiting

OVERALL STUDY PRINCIPAL INVESTIGATOR:
David Kirsch, MD, PhD
Head, Radiation Medicine Program, Princess Margaret Cancer Centre; Head, Department of Radiation Oncology, University Health Network; Senior Scientist, Princess Margaret Cancer Centre; Peter and Shelagh Godsoe Chair in Radiation Medicine; Professor, Departments of Radiation Technology & Medical Biophysics, University of Toronto
Princess Margaret Cancer Centre, University Health Network

CLINICALTRIALS.GOV IDENTIFIER: NCT03092323

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study view Dr. Kirsch’s SARC032 presentation at the 2021 SARC Semiannual Meeting:

To contact the study research staff: